Featured Research

from universities, journals, and other organizations

Genetic Testing Not Cost-effective In Guiding Initial Dosing Of Common Blood Thinner

Date:

January 23, 2009

Source:

University of Cincinnati

Summary:

New analyses show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding.

Share This

New analyses led by the University of Cincinnati (UC) show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding.

Mark Eckman, MD, professor of medicine at UC and lead investigator of the study, says the U.S. Food and Drug Administration changed the labeling for warfarin in 2007, suggesting that clinicians consider genetic testing before initiating therapy.

"There are certain genes that are known to contribute to an increased sensitivity to warfarin," he says. "The idea behind genetic testing—also known as pharmacogenetic-guided dosing— is to help guide the initial, and possibly lower, dose of warfarin for patients found to possess certain variants of the genes cytochrome P450 CYP2C9 and vitamin K epoxide reductase, or VKORC1. The hope is that more accurate dosing will translate into decreased major bleeds during the initiation phase of warfarin dosing, which is the first month or so."

Eckman says the study looked at whether the benefit of testing is worth the costs associated with it.

Researchers first performed an analysis combining the results of the only three clinical studies published to date to determine the degree to which pharmacogenetic-guided dosing decreases the risk of major bleeds when compared with standard induction of treatment with warfarin.

The team next constructed a model to estimate the cost-effectiveness of a genotype-guided dosing strategy.

While they found that genotype-guided dosing resulted in better outcomes, it was at a relatively high cost—over $170,000 per quality-adjusted life year gained.

In other analyses, where they took into consideration the limitations of the studies, researchers found that there is only a 10 percent chance that genotype-guided dosing is likely to be cost-effective.

Researchers also looked at the impact of other variables on the cost-effectiveness of genotype-guided dosing.

Eckman says results show that genotype-guided dosing might be worth the costs if it:

Is used for patients at high risk for hemorrhage

Prevents more than 32 percent of major bleeding events

Is available within 24 hours

Costs less than $200

"This could be accomplished if testing were done in-house, at lower cost and without delays," he says, noting that currently in most cases these tests need to be sent to outside laboratories which can lead to delays in starting treatment and increased cost. "Furthermore, future studies, such as the recently funded National Institutes of Health COAG trial, need to examine the impact of pharmacogenetic-guided dosing on bleeding risk and monitor outcomes long enough to determine the true duration of benefit."

Eckman also suggests that rather than excluding patients at higher risk for bleeding, studies should offer enrollment if it has already been determined that these patients require warfarin.

"Personalized, predictive medicine offers great promise, but we need to carefully examine the benefits and understand the cost-effectiveness of such strategies before we spend a lot of money on very expensive tests."

This study is being published in the Jan. 20, 2009, edition of Annals of Internal Medicine.

Researchers at Washington University and Massachusetts General Hospital were also involved in this study.

University of Cincinnati. "Genetic Testing Not Cost-effective In Guiding Initial Dosing Of Common Blood Thinner." ScienceDaily. ScienceDaily, 23 January 2009. <www.sciencedaily.com/releases/2009/01/090119210421.htm>.

University of Cincinnati. (2009, January 23). Genetic Testing Not Cost-effective In Guiding Initial Dosing Of Common Blood Thinner. ScienceDaily. Retrieved March 3, 2015 from www.sciencedaily.com/releases/2009/01/090119210421.htm

University of Cincinnati. "Genetic Testing Not Cost-effective In Guiding Initial Dosing Of Common Blood Thinner." ScienceDaily. www.sciencedaily.com/releases/2009/01/090119210421.htm (accessed March 3, 2015).

More From ScienceDaily

More Health & Medicine News

Featured Research

Mar. 3, 2015 — New assays can detect malaria parasites in human blood at very low levels and might be helpful in the campaign to eradicate malaria, reports a new study. An international team led by Ingrid Felger, ... full story

Mar. 3, 2015 — Adults over the age of 30 only catch flu about twice a decade, a new study suggests. So, while it may feel like more, flu-like illness can be caused by many pathogens, making it difficult to assess ... full story

Mar. 3, 2015 — No significant change in home habits of smokers have been observed in the aftermath of a ban on smoking in public spaces, researchers report. Greater inspiration to kick the habit likely comes from ... full story

Mar. 3, 2015 — Heart function has been associated with the development of dementia and Alzheimer's disease through a new study. Participants with decreased heart function, measured by cardiac index, were two to ... full story

Mar. 3, 2015 — Children of recently separated or divorced families are likelier to drink sugar-sweetened beverages than children in families where the parents are married, putting them at higher risk for obesity ... full story

Mar. 3, 2015 — Gastric bypass and similar stomach-shrinking surgeries are a popular option for obese patients looking to lose weight or treat type 2 diabetes. While the surgeries have been linked to a decreased ... full story

Mar. 3, 2015 — Most people consume more salt than they need and therefore have a higher risk of heart disease and stroke, which are the two leading causes of death worldwide. But a new study reveals that dietary ... full story

Mar. 3, 2015 — Twice as many children born to mothers who took antibiotics during pregnancy were diagnosed with asthma by age 3 than children born to mothers who didn’t take prenatal antibiotics, a new study has ... full story

Mar. 3, 2015 — Although sedatives are often administered before surgery, a randomized trial finds that among patients undergoing elective surgery under general anesthesia, receiving the sedative lorazepam before ... full story

Featured Videos

Mom Triumphs Over Tragedy, Helps Other Families

AP (Mar. 3, 2015) — After her son, Dax, died from a rare form of leukemia, Julie Locke decided to give back to the doctors at St. Jude Children&apos;s Research Hospital who tried to save his life. She raised $1.6M to help other patients and their families. (March 3)
Video provided by AP

Looted and Leaking, South Sudan's Oil Wells Pose Health Risk

AFP (Mar. 3, 2015) — Thick black puddles and a looted, leaking ruin are all that remain of the Thar Jath oil treatment facility, once a crucial part of South Sudan&apos;s mainstay industry. Duration: 01:13
Video provided by AFP

Woman Convicted of Poisoning Son

AP (Mar. 3, 2015) — A woman who blogged for years about her son&apos;s constant health woes was convicted Monday of poisoning him to death by force-feeding heavy concentrations of sodium through his stomach tube. (March 3)
Video provided by AP

Related Stories

Nov. 3, 2014 — Patients with atrial fibrillation who take the blood thinner dabigatran are at greater risk for major bleeding and gastrointestinal bleeding than those who take warfarin, according to a new study. ... full story

Feb. 24, 2014 — An updated guideline recommends that people with nonvalvular atrial fibrillation, or irregular heartbeat, take oral anticoagulants, a type of blood thinner pill, to prevent ... full story

Oct. 1, 2012 — A new anticoagulant called apixaban is superior to warfarin in preventing stroke with consistent effects across a wide range of stroke and bleeding risk in patients with atrial fibrillation, ... full story

Aug. 10, 2011 — Patients with an irregular heartbeat could benefit from a drug that is easier to administer than the current standard treatment. The condition, which is more common with older age, can lead to blood ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.